第4名：BioGen制药公司

    交易代码: BIIB

    年初至今股票涨幅: 69%

    市值: 266亿美元

    500强排名: 476

    制药公司BioGen的股价上涨是源于其治疗多发性硬化症的药物BG-12有希望获得美国食品和药物管理局（Food and Drug Administration）的批准。

    BioGen开发治疗多发性硬化症、癌症和其他疾病的药物。投资者最关注的是BioGen治疗多发性硬化症药物的前景，分析师们预测这款药物的市场规模可能高达数十亿美元。

    10月份，BioGen宣布，三期临床试验显示，服用BG-12的患者其多发性硬化症复发率显著下降。

    分析师们估计BG-12的市场规模可能达到20-30亿美元，成为大多数多发性硬化症患者的主要治疗用药。BioGen计划2012年初向美国食品和药物管理局提交新药申报。

    BG-12将丰富该公司现有的药品组合。凭借现有的药品组合，BioGen第三季度净利润增长了38%。

#4 BioGen

    Ticker: BIIB

    YTD stock performance: 69%

    Market cap: $26.6 billion

    Fortune 500 Rank: 476

    Shares of pharmaceutical maker BioGen spiked on hopes that the company could get its multiple sclerosis pill, BG-12, approved by the Food and Drug Administration.

    BioGen develops treatments for multiple sclerosis, cancer and other diseases. Investors are most focused on the prospects for BioGen's MS treatment as analysts have speculated that it could be a billion dollar drug.

    In October, BioGen said that patients using BG-12 during a third clinical trial showed significant drops in MS relapse rates.

    Analysts estimate that BG-12 could be a $2 billion to $3 billion drug, and become the primary treatment for most MS sufferers. BioGen plans to file for approval with the FDA in early 2012.

    BG-12 would round out the company's existing drug portfolio, which helped boost BioGen's third-quarter net income by 38%.